The unexpected link between weight loss drugs and alcohol-related hospital visits
- A new analysis suggests that GLP-1 weight loss drugs, including Wegovy and Mounjaro, could significantly reduce alcohol-related hospital admissions.
- The study, published in BMJ Open, analysed data from 40,703 individuals who began taking semaglutide or tirzepatide between January 2018 and December 2024.
- GLP-1 drugs were associated with a 26 per cent lower risk of alcohol-related hospital admission compared to other diabetes medications.
- Among those using the drugs for weight loss, the risk was 32 per cent lower, while for type 2 diabetics and obese individuals with alcohol problems, reductions were 63 per cent and 65 per cent respectively.
- Researchers suggest a potential role for GLP-1 medications in alcohol use disorder, though experts note that further research is required, particularly given the observational nature of the study and the cost of the drugs.
Weight-loss drugs Wegovy and Mounjaro could slash alcohol-related hospital admissions

Thank you for registering
Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in



